Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Safety Study of Teduglutide in Japanese Pediatric Short Bowel Syndrome Patients
jRCT2021210035Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Number of Participants With Serious Adverse Events (SAEs) and 9 more. Started Jan 2022; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on jRCT2021210035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210035.